Aurora Cannabis Reveals Latest Product Innovations: Ultra-High Potency Indicas And Strains For Veterans
Aurora Cannabis Reveals Latest Product Innovations: Ultra-High Potency Indicas And Strains For Veterans
"As a company committed to leading the way in terms of cannabis innovation, we are dedicated to putting patients first by harnessing the innovative solutions developed by our top researchers at Aurora Coast, our unique global research facility," Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), announced on Tuesday developments in cannabis science from Aurora's research and genetics facility, Aurora Coast.
极光大麻股公司（纳斯达克:ACB）（tsx:ACB）宣布，周二在极光研究和遗传科学设施Aurora Coast的大麻科学领域取得了进展。
The latest innovations from the Canadian medical cannabis giant include:
加拿大医疗大麻巨头的最新创新包括：
- Aurora | CBD Varius (1g, 510 Cartridge);
- MedReleaf (Strains For Heroes) | Esprit De Corps (5g and 15g); a premium sativa (THC: 20-29%, CBD: 0-1%), developed under the Strains For Heroes initiative by Aurora with direct feedback from Veteran patients;
- MedReleaf | Sedamen (1g, 510 Cartridge) in a higher THC format;
- MedReleaf | Noculus (5g and 15g); an ultra-high potency indica, featuring THC levels between 25-31% and CBD content from 0-1%; and
- WMMC | Seasonal Stash – Frosted Alpine (10g); a limited-grown hybrid strain (THC: 24-30%; CBD: 0-1%).
- 极光 | CBD吸入器（1克，510毫米）；
- MedReleaf（英雄品种）| Esprit De Corps（5g和15g）；一种优质的萨提瓦（THC: 20-29%，CBD: 0-1%），由极光在英雄品种倡议下，与退伍军人患者直接反馈合作开发；
- MedReleaf | Sedamen（1g，510毫米）以更高THC格式提供；
- MedReleaf | Noculus（5g和15g）；一种超高效力的靛青品种，THC含量介于25-31%，CBD含量在0-1%之间；和
- WMMC | 季节性储藏品 – 霜冻高山（10g）；一种限量生产的杂交品种（THC: 24-30%，CBD: 0-1%）。
Read Also: Aurora Cannabis Launches Innovative THC Oil Products In Australia To Meet Diverse Patient Needs
阅读更多：极光大麻在澳洲推出创新THC油产品，以满足不同患者需求
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
- 订阅本新闻快讯，每天免费获取Benzinga独家分析和大麻股行业及市场的最新资讯。如果您对业务认真，不容错过。在这里订阅我们的新闻简报。
"As a company committed to leading the way in terms of cannabis innovation, we are dedicated to putting patients first by harnessing the innovative solutions developed by our top researchers at Aurora Coast, our unique global research facility," Lana Culley, vice president of science and innovation at Aurora. "We strive to continuously raise the bar on product superiority and overall user experience so that we can deliver on our mission of providing patients with access to the very best medical cannabis."
作为一家致力于在大麻股创新领域处于领先地位的公司，我们致力于通过利用极光海岸顶尖研究人员在全球独特研究设施开发的创新解决方案，将患者放在首位，"极光科学和创新副总裁拉娜·卡利说。"我们努力不懈地提升产品优势和用户体验，以便实现我们的使命，为患者提供最优质的医用大麻。"
The latest update from Aurora comes on the heels of its recently revealed lineup of innovations from Greybeard, San Rafael '71 and Tasty's brands for Canadian consumers.
极光最新的消息发布是在其最近公布的创新产品系列（来自Greybeard，San Rafael '71和Tasty's品牌）之后，面向加拿大消费者。
Aurora reported its second quarter financial results, showing revenue of CA$81.1 million ($58.3 million), up from CA$63.1 million in the same period last year.
极光报告了其第二季度财务业绩，显示营业收入为CA$8110万（$5830万），较去年同期的CA$6310万有所增长。
The company attributed the 29% increase from the prior period to 41% growth in its global medical cannabis business and 21% growth in its plant propagation business, slightly offset by lower quarterly revenue in its consumer cannabis business.
公司表示，与前一时期相比增长29%，其中全球医疗大麻业务增长41%，植物繁殖业务增长21%，略有偏低的消费大麻业务季度收入。
- UK Medical Cannabis Market Gets Boost With Aurora And Script Assist Collaboration
- 极光与Script Assist合作，为英国医疗大麻市场注入活力。
ACB Price Action
ACB的价格行情
Aurora's shares traded 3.28% lower at $4.42 per share at the time of writing on Tuesday morning.
在周二早上写作时，极光股价为每股4.42美元，下跌了3.28%。
译文内容由第三方软件翻译。
